Reversing the Effects of Factor 10A Inhibitors in Intracranial Hemorrhage

The chapter explores the challenges and potential solutions for reversing the effects of Factor 10A inhibitors in patients with intracranial hemorrhage (ICH), emphasizing the risks associated with these inhibitors and the impact on patient outcomes. It discusses the use of Index and Alpha as decoy molecules to bind Factor 10A inhibitors and improve outcomes, along with the role of PCC as a reversal agent before the introduction of specific targeted agents. The chapter also delves into the NEXA IV study and the design considerations for trials like InexaI, shedding light on the importance of trial design in assessing the efficacy of anticoagulant reversal strategies.